Specialty & Generic Drug Manufacturer Stocks
38 US-listed specialty & generic drug manufacturer companies above our tradable floor ($5 and $1 million a day), largest first, with each one's stage, price and valuation after the close.
38
companies
16 (42%)
in a Stage 2 uptrend
+9.5%
3-month return, weighted by size
7 · 3 · 12
in Stage 1 · 3 · 4
Only the Stage 2 ones →Filter them in the screener →All Health Care stocks →Industry rotation →
Every specialty & generic drug manufacturer stock we cover
| Stock | Stage | Close | Day | 3 months | From high | RS | P/E | Yield | Market cap |
|---|---|---|---|---|---|---|---|---|---|
| TAKTakeda Pharmaceutical | Stage 2, wk 12 | $20.91 | +4.5% | +24.2% | 0.0% | 86 | — | 3.09% | $66.8B |
| TEVATeva Pharmaceutical Industries | Stage 2, wk 11 | $42.09 | +1.5% | +22.1% | 0.0% | 95 | 67.0 | — | $49.1B |
| HLNHaleon | Stage 4, wk 5 | $8.66 | +1.1% | -11.1% | -21.6% | 52 | 21.2 | 1.98% | $38.1B |
| ZTSZoetis | Stage 1, wk 1 | $79.72 | +1.2% | +3.4% | -43.9% | 27 | 13.5 | 2.66% | $32.9B |
| UTHRUnited Therapeutics | Stage 1, wk 2 | $598.72 | +0.9% | +16.0% | 0.0% | 77 | 20.9 | — | $25.7B |
| VTRSViatris | Stage 2, wk 57 | $19.04 | -0.9% | +8.8% | -0.9% | 94 | — | 2.60% | $21.9B |
| NBIXNeurocrine Biosciences | Stage 4, wk 1 | $146.10 | -0.2% | -12.1% | -21.2% | 58 | 21.0 | — | $14.9B |
| RDYDr. Reddy's Laboratories | Stage 1, wk 3 | $14.17 | +0.4% | +17.4% | -7.2% | 58 | 30.1 | 0.63% | $11.8B |
| ELANElanco Animal Health | Stage 4, wk 5 | $23.06 | -0.8% | -10.3% | -14.1% | 55 | — | — | $11.5B |
| ALKSAlkermes | Stage 3, wk 7 | $45.34 | -0.1% | -8.5% | -17.9% | 83 | 116.3 | — | $7.6B |
| AMRXAmneal Pharmaceuticals | Stage 2, wk 21 | $21.51 | +0.7% | +14.1% | 0.0% | 95 | 41.8 | — | $7.5B |
| KNSAKiniksa Pharmaceuticals International | Stage 2, wk 74 | $92.24 | -5.5% | +25.7% | -5.5% | 97 | 81.6 | — | $7.2B |
| LNTHLantheus Holdings | Stage 3, wk 8 | $100.46 | +0.1% | -0.7% | -9.4% | 92 | 24.2 | — | $6.6B |
| HIMSHims & Hers Health | Stage 3, wk 8 | $27.68 | -6.7% | -10.2% | -39.1% | 28 | — | — | $6.5B |
| INDVIndivior Pharmaceuticals | Stage 4, wk 2 | $35.37 | +0.3% | -5.4% | -15.4% | 82 | 12.7 | — | $4.2B |
| LQDALiquidia | Stage 4, wk 1 | $45.06 | +0.2% | -46.3% | -50.5% | 95 | 28.6 | — | $4.0B |
| AMLXAmylyx Pharmaceuticals | Stage 2, wk 17 | $28.86 | +0.6% | +43.1% | -27.2% | 95 | — | — | $3.6B |
| RGCRegencell Bioscience Holdings | Stage 1, wk 5 | $6.71 | -2.2% | +9.5% | -87.3% | 19 | — | — | $3.3B |
| BHCBausch Health Companies | Stage 2, wk 7 | $8.20 | -8.0% | +17.1% | -8.0% | 81 | — | — | $3.1B |
| SUPNSupernus Pharmaceuticals | Stage 4, wk 7 | $41.92 | +0.2% | -8.9% | -26.5% | 36 | — | — | $2.4B |
| PBHPrestige Consumer Healthcare | Stage 4, wk 5 | $49.06 | +0.6% | -5.5% | -30.1% | 40 | 13.9 | — | $2.3B |
| PRGOPerrigo | Stage 2, wk 8 | $15.78 | -0.8% | +50.8% | -18.5% | 39 | — | 7.29% | $2.2B |
| BCRXBioCryst Pharmaceuticals | Stage 4, wk 1 | $8.47 | -0.6% | -3.9% | -23.8% | 66 | — | — | $2.2B |
| TRLVTrulieve Cannabis Corp. Subordinate Voting Shares | Stage 2, wk 12 | $10.28 | -3.0% | +19.5% | -20.9% | 83 | — | — | $2.0B |
| XERSXeris Biopharma Holdings | Stage 2, wk 15 | $10.71 | -0.4% | +31.7% | -3.8% | 62 | — | — | $2.0B |
| ANIPANI Pharmaceuticals | Stage 4, wk 10 | $72.00 | -1.6% | -10.1% | -23.8% | 38 | 16.0 | — | $1.7B |
| PAHCPhibro Animal Health | Stage 1, wk 11 | $38.88 | +0.1% | +5.0% | -34.3% | 50 | 16.4 | 1.22% | $1.6B |
| ETONEton Pharmaceuticals | Stage 2, wk 31 | $52.18 | -2.8% | +15.6% | -19.0% | 98 | 125.0 | — | $1.5B |
| PCRXPacira BioSciences | Stage 2, wk 3 | $36.39 | 0.0% | +35.2% | -0.1% | 91 | 103.8 | — | $1.5B |
| AMPHAmphastar Pharmaceuticals | Stage 2, wk 5 | $27.72 | +2.9% | +37.1% | -5.7% | 64 | 15.4 | — | $1.2B |
| HROWHarrow | Stage 4, wk 7 | $28.24 | -5.8% | -27.8% | -48.5% | 37 | — | — | $1.1B |
| COLLCollegium Pharmaceutical | Stage 4, wk 12 | $23.80 | -1.0% | -33.1% | -52.2% | 33 | 18.5 | — | $775M |
| EOLSEvolus | Stage 2, wk 19 | $7.35 | -2.3% | +21.5% | -21.0% | 59 | — | — | $485M |
| TKNOAlpha Teknova | Stage 2, wk 19 | $7.36 | -9.0% | +38.9% | -21.1% | 80 | — | — | $454M |
| EBSEmergent BioSolutions | Stage 1, wk 1 | $6.81 | -5.7% | -8.1% | -51.0% | 35 | — | — | $349M |
| ANIKAnika Therapeutics | Stage 2, wk 16 | $20.95 | -3.9% | +1.0% | -4.9% | 96 | — | — | $280M |
| BIOABioAge Labs | Stage 4, wk 9 | $5.87 | -1.2% | -45.5% | -76.6% | 37 | — | — | $269M |
| LFCRLifecore Biomedical | Stage 1, wk 4 | $6.40 | -1.8% | +45.8% | -27.4% | 47 | — | — | $243M |
Specialty & Generic Drug Manufacturer Stocks: quick answers
How many specialty & generic drug manufacturer stocks are in an uptrend?
As of Oct 30, 2026, 16 of the 38 US-listed specialty & generic drug manufacturer stocks we cover are in Stage 2, the uptrend phase, including Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), Viatris (VTRS), Amneal Pharmaceuticals (AMRX) and Kiniksa Pharmaceuticals International (KNSA).
What is the largest specialty & generic drug manufacturer stock?
Takeda Pharmaceutical (TAK), with a market value of $66.8B. It closed at $20.91 on Oct 30, 2026, in Stage 2.
Which specialty & generic drug manufacturer stocks are near their 52-week high?
As of Oct 30, 2026, 6 are within 5% of a 52-week high: Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), United Therapeutics (UTHR), Viatris (VTRS), Amneal Pharmaceuticals (AMRX) and Xeris Biopharma Holdings (XERS).
End-of-day data for common stocks and ADRs on the NYSE, Nasdaq and NYSE American, computed after each US close and dated to the trading session.